



LA REALTÀ ITALIANA DELLA CIRROSI EPATICA | VENERDÌ 19 MARZO 2021
TRA TERAPIE E IMPATTO SOCIO ECONOMICO




Fabio Cartabellotta

Direttore UOC Medicina Interna Ospedale Buccheri La Ferla
Palermo, Responsabile Rete HCV Sicilia




Modello Multi-Stage per il decorso clinico della Cirrosi Epatica

- Il passaggio dalla Cirrosi Compensata alla Cirrosi Scompensata si verifica con una frequenza di circa il 5-7% all'anno
- La Cirrosi Epatica Scompensata e' una malattia sistemica che induce patologia multiorganica




EASL CPG decompensated cirrhosis. J Hepatol 2018;doi: 10.1016/j.jhep.2018.03.024




Andamento del tasso di mortalità per Cirrosi epatica. Sicilia 2010-2018

Dati forniti dall'Osservatorio Epidemiologico dell'Assessorato della Salute

Anno	Cirrosi			
	Numero Decessi	Tasso standardizzato	L.inf.	L.sup.
2010	958	12,09	11,3	12,93
2011	957	12,08	11,29	12,93
2012	845	10,37	9,65	11,14
2013	843	10,2	9,49	10,97
2014	829	9,41	8,75	10,12
2015	799	9,06	8,41	9,76
2016	693	7,91	7,31	8,57
2017	700	7,48	6,9	8,1
2018 (escluso Trapani)	595	7,2	6,6	7,84







Andamento del tasso di mortalità per tumore del fegato. Sicilia 2010-2018

Dati forniti dall'Osservatorio Epidemiologico dell'Assessorato della Salute


Anno	Numero decessi	Tasso standardizzato	L.inf.	L.sup.
2010	1.014	12,21	11,44	13,04
2011	1.045	12,31	11,54	13,13
2012	1.005	11,82	11,07	12,63
2013	1.039	11,93	11,18	12,73
2014	1.049	11,86	11,12	12,65
2015	1.026	11,29	10,58	12,06
2016	953	10,34	9,66	11,07
2017	980	10,73	10,03	11,47
2018 (escluso Trapani)	843	9,77	9,09	10,5






Changing Etiology of chronic liver disease associated with HCC


5192 Patients with HCC (3.5% NAFLD/NASH, 4.4% Cryptogenic)
recorded from 2000 to 2014




Bucci et al for ITALICA, Liv Int 2017





HCV: evoluzione della cura





RETE SICILIA SELEZIONE TERAPIA HCV (RESIST-HCV): LA STRUTTURA (decreti assessoriali n.215 del 12 febbraio 2015 e n. 638 del 15.4.2019)






COORTE 2015-2017

Diagnosi della malattia di fegato per coorte di nascita e per genere in 8606 pazienti trattati con DAA da marzo 2015 a dicembre 2017

	Ep cronica	Cirrosi
Maschi	2032 (41%)	2909 (59%)
Femmine	1619 (41%)	2046 (59%)
Totale	3651 (43%)	4955 (57%)

Dati RESIST HCV Sicilia







COORTE 2018-2020

Diagnosi della malattia di fegato per coorte di nascita e per genere in 6.453 pazienti trattati con DAA da gennaio 2018 a settembre 2020


	Ep cronica	Cirrosi
Maschi	2761 (77%)	810 (23%)
Femmine	2391 (82%)	494 (18%)
Totale	5152 (80%)	1303 (20%)


Dati RESIST HCV Sicilia






Paradox of hepatitis C: transforming individual care without reaching the population







Pazienti con malattia cronica di fegato da HCV diagnosticati e trattati in Sicilia

Provincia	POPOLAZIONE PROVINCIA	PAZIENTI	TERAPIE	RAPPORTO PAZIENTI/POPOLAZIONE REGISTRATI/TRATTATI
PALERMO	1.275.598	6724	5430	0,52/0,41
CATANIA	1.109.704	4160	3431	0,37/0,30
MESSINA	631.371	1553	1341	0,23/0,19
AGRIGENTO	438.831	611	514	0,25/0,20
TRAPANI	432.150	724	570	0,22/0,16
SIRACUSA	400.847	1505	1313	0,47/0,39
RAGUSA	321.249	2174	1757	0,54/0,42
CALTANISSETTA	266.731	660	561	0,39/0,31
ENNA	166.456	379	275	0,31/0,22
SICILIA	5.026.898	18490	15192	0.36/0,30





PAZIENTI TRATTATI IN SICILIA (2015-2020)





RETE PER LA DIAGNOSI E TERAPIA DELL'EPATITE CRONICA DA HCV IN SICILIA (Progetti di linkage to care)





epatite C ?
...no, grazie

esiste una **CURA** CHE **PERMETTE**
DI GUARIRE DALL'EPATITE C

Progetto HCV patient journey OSPEDALE BUCCHERI LA FERLA (Fatebenefratelli) – Palermo

Sconfiggere l'epatite C


- Screening di tutti i pazienti ricoverati di età compresa fra 40 e 80 anni
- Consulenza epatologica

La terapia è accessibile a tutti GRATUITAMENTE

 Servizio call center 392-0558659 attivo dal lunedì al venerdì dalle ore 9.00 alle ore 12 e dalle ore 16.00 alle ore 18.00

«Con il contributo incondizionato»  GILEAD

Progetto grafico: Claude Farini - email: claudiefarini@gmail.com




Progetto HCV: Patient Journey Ospedale Buccheri La Ferla - Palermo

	Anti HCV negativity n =3143/3311 (95%)	Anti HCV positivity n =168/3311 (5%)
Sex		
Male	<u>1647(52.4%)</u>	<u>82 (48.8%)</u>
Female	<u>1496(47.6%)</u>	<u>86 (51,2%)</u>
Age		
<40 years	361(11,5%)	4 (2,5%)
40-60 years	555(17,6%)	26 (15,5%)
60-80 years	<u>1490 (47,4%)</u>	<u>74 (44%)</u>
> 80 years	736 (23,5%)	64 (38%)
HCV RNA quantitative		
• Positive Treated with DAAs	---	36(21,4%) 16
• Negative SVR		86(51,1%) 22
• Not available		46 (27,3%)


Characteristics of consecutively enrolled patients, subjected to a screening for Anti HCV, from November 2019 to February 2021

Hospital Buccheri La Ferla, wards involved : Internal Medicine , Oncology, Neurology, Cardiology/ UTIC, Ortopedy, General Surgery, Rehabilitation, Day Service and Day Hospital, CUP




The changes of HBV liver disease (Therapeutic regimes)

DRUGS	FIRSTS THERAPY		LAST THERAPY	
	Number of patients	%	Number of patients	%
LAMIVUDINE	108	35.6	14	4.6
ADEFOVIR	19	6.3	1	0.3
LAM + ADV	13	4.3	7	2.3
TELBIVUDINE	10	3.3	4	1.3
ENTECAVIR	110	36.3	114	86%
TENEFVIR	43	14.2	136	
ENT + TDV	-		8	
TELB+TDV	-		1	
DISCONTINUED	-		18	5.9



The changes of HBV liver disease (disease pattern)


	First Cohort	Second Cohort
Years of observation	1982 - 1991	1996-2017
Number of patients	302	303
Mean follow-up (Months)	94 ± 37	100 ± 67
Age (mean ± SD)	34 ± 15	51 ± 13
Gender (M %)	71	75
Viral pattern		
• HBeAg positive	86 (28%)	56 (18.5%)
• HBeAg negative	80 (26%)	247 (81.5%)
• Anti-HDV positive	76 (25%)	19 (6.3%)
• Anti-HCV positive	20 (7%)	8 (2.6%)
Disease pattern		
• Chronic hepatitis	216 (81.5%)	154 (51%)
• Compensated cirrhosis	86 (28.5%)	149 (49%)
Esophageal varices in cirrhosis		
• Present		85 (57%)
• Absent		64 (43%)




The Epidemic of NAFLD in Italy

What Forecast?


Incident Decompensated Cirrhosis, HCC and Liver-Related Deaths among Prevalent NAFLD Population




Estes et al, JHEP 2018




The Epidemic of NAFLD: Data from Palermo General Population




Petta S et al, Liv Int 2018





TRATTAMENTI AVVIATI RETEHCV 2019/2020







PAZIENTI AVVIATI ALLA DIAGNOSI RETEHCV 2019/2020






VISITE DI FOLLOW-UP RETEHCV 2019/2020






Cirrhosis: The Lesson from COVID-19

AISF survey: **Visite in Cirrosi Compensata**




Available at: https://www.webaisf.org/wp-content/uploads/2020/05/Report_Survey_110520MM.pdf




Cirrhosis: The Lesson from COVID-19

AISF survey: **Visite in Cirrosi Scompensata**




Available at: https://www.webaisf.org/wp-content/uploads/2020/05/Report_Survey_110520MM.pdf




Cirrhosis: The Lesson from COVID-19

AISF survey: **Valutazione Pre-Trapianto di Fegato**



Nei pazienti con indicazione a trapianto epatico la valutazione pre-trapianto ha subito variazioni?

Available at: [https://www.webaisf.org/wp-content/uploads/2020/05/Report Survey 110520MM.pdf](https://www.webaisf.org/wp-content/uploads/2020/05/Report_Survey_110520MM.pdf)



Rete in Epatologia

Condivisoni di Strategie e di Risorse

Equità



Misurazioni di Outcomes

HCV


HBV

NAFLD

Malattie
Autoimmuni
Colestatiche

HCC

.....



Rete Epatologica

The Bridge from HCV hepatitis therapy to liver disease management

SINTESI

Sicilian Network for Therapy, Epidemiology and Screening in Hepatology


NALFD/NASH

Hepatocellular Carcinoma

CBP

HBV

HCV



Multidisciplinary Assessment of Cirrhotic Patients



Laboratorio di Ecografia e Elastografia

- Ecografia
- Fibroscan



Laboratorio di chimica clinica

- Esami ematologici e biochimici



Farmacia

- Gestione e distribuzione dei farmaci



Laboratorio di endoscopia


- Diagnosi di ipertensione portal



Day Hospital per paracentesi



Gestione domiciliare EPS e cure palliative



Cirrhosis: The Lesson from COVID-19

The need for Telemedicine

